Nicole Blackman
Overview
Explore the profile of Nicole Blackman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acheampong P, Mensah K, Owusu-Dabo E, Rodas J, Rouleau K, Wilson J, et al.
Can Fam Physician
. 2025 Feb;
71(2):88-90.
PMID: 39965972
No abstract available.
2.
Acheampong P, Mensah K, Owusu-Dabo E, Rodas J, Rouleau K, Wilson J, et al.
Can Fam Physician
. 2025 Feb;
71(2):e26-e28.
PMID: 39965962
No abstract available.
3.
Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial
Ezekowitz J, Mulder H, Mentz R, Butler J, DE Pasquale C, Lewis G, et al.
J Card Fail
. 2025 Jan;
PMID: 39890013
Background: The HEART-FID trial (Randomized Placebo-Controlled Trial of Ferric Carboxymaltose [FCM] as Treatment for Heart Failure with Iron Deficiency) is the largest trial to test intravenous iron (ferric carboxymaltose [FCM])...
4.
Nouhravesh N, Garg J, Rockhold F, DE Pasquale C, OMeara E, Lewis G, et al.
Eur J Heart Fail
. 2024 Jun;
PMID: 38896006
Aims: Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced...
5.
Harrington J, Mentz R, Rockhold F, Garg J, Butler J, DE Pasquale C, et al.
Circ Heart Fail
. 2024 Jan;
17(2):e010676.
PMID: 38250799
Background: Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the...
6.
Mentz R, Garg J, Rockhold F, Butler J, DE Pasquale C, Ezekowitz J, et al.
N Engl J Med
. 2023 Aug;
389(11):975-986.
PMID: 37632463
Background: Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effects...
7.
Ponikowski P, Mentz R, Hernandez A, Butler J, Khan M, Van Veldhuisen D, et al.
Eur Heart J
. 2023 Aug;
44(48):5077-5091.
PMID: 37632415
Background And Aims: Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated,...
8.
Harrington J, Mentz R, Rockhold F, Garg J, Butler J, DE Pasquale C, et al.
Am Heart J
. 2023 Aug;
266:25-31.
PMID: 37598795
Background: Prior clinical trials have investigated intravenous iron in patients with heart failure (HF) and iron deficiency, but the safety and efficacy of this therapy remains unclear. Methods: We report...
9.
Korczowski B, Farrell C, Falone M, Blackman N, Rodgers T
Pediatr Res
. 2023 May;
94(4):1547-1554.
PMID: 37208431
Background: Iron deficiency is the primary cause of anemia in children. Intravenous (IV) iron formulations circumvent malabsorption and rapidly restore hemoglobin. Methods: This Phase 2, non-randomized, multicenter study characterized the...
10.
Makharadze T, Boccia R, Krupa A, Blackman N, Henry D, Gilreath J
Am J Hematol
. 2021 Oct;
96(12):1639-1646.
PMID: 34653287
Erythropoiesis-stimulating agents (ESA) are effective for chemotherapy-induced anemia (CIA) but associated with serious adverse events. Safer alternatives would be beneficial in this population. The efficacy and safety of ferric carboxymaltose...